Form 4: Guardant Health Director Sells 100 Shares Under Pre-Arranged Trading Plan

Guardant Health Director Meghan V. Joyce reported the sale of 100 shares of common stock at $41.66 per share, executed under a Rule 10b5-1 trading plan.

Summary

• Meghan V. Joyce, a Director at Guardant Health, Inc. (GH), reported a transaction involving the company's common stock.
• On June 2, 2025, Ms. Joyce disposed of 100 shares of Guardant Health common stock.
• The shares were sold at a price of $41.66 per share.
• Following this transaction, Ms. Joyce beneficially owns 7,746 shares of Guardant Health common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan, indicating it was pre-scheduled.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive to neutral. While it's an insider sale, the small quantity and the execution under a Rule 10b5-1 plan mitigate any negative implications, suggesting a pre-planned financial management activity rather than a loss of confidence.

Positives

• The transaction was executed under a Rule 10b5-1 trading plan, indicating a pre-scheduled sale rather than a reactive decision, which can reduce concerns about insider sentiment.
• The number of shares sold (100) is a very small fraction of the total shares beneficially owned (7,746), suggesting minimal impact on the director's overall stake in the company.

Negatives

• An insider sale, even if pre-scheduled, can sometimes be perceived negatively by investors as it reduces the insider's direct equity exposure to the company.

Risks

• No specific risks are detailed within this Form 4 filing itself, as it primarily reports a transaction.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This specific insider transaction report does not provide information to analyze broader industry trends or competitive landscape. It is a routine disclosure of an individual's stock activity.

Stakeholder Impact

• Shareholders: Minimal direct impact due to the small number of shares sold, especially given the pre-scheduled nature of the transaction.
• Employees, Customers, Suppliers, Creditors: No direct impact from this specific filing.

Key Dates

Keywords

Guardant Health, GH, Form 4, Insider Trading, Stock Sale, Director, Meghan V. Joyce, Rule 10b5-1, Beneficial Ownership